Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Atlas Copco completes acquisition of a US based cryostat manufacturer

Nacka, Sweden, 21 Nov 2022: Atlas Copco has completed the acquisition of Montana Instruments Corporation, which was announced in August. The company provides cryostat solutions for customers involved in physics research and low temperature technology solutions.Montana Instruments Corporation is a privately owned company with 38 employees, located in Bozeman, Montana, USA. In 2021, the company had revenues of approximately MUSD 12 (MSEK 106*). The purchase price is not disclosed. The company will become part of the Scientific Vacuum division within the Vacuum Technique Business Area.

Interim Financial Report – first nine months of 2022 (Q3 2022)

21 November Company2022                                                               announcement no. 60 Today, SGL International A/S has published its Interim Financial Report for the first nine months of 2022 (Q3 2022). SGL Group (SGL International A/S) · For SGL Group, the Q3 2022 revenue was DKK 4,419m versus DKK 2,641m in Q3 2021; an increase of 67%, primarily driven higher activity levels and larger share of wallet with both new and existing

Medivir recruits Pia Baumann as new Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Pia Baumann has been recruited as its new Chief Medical Officer (CMO). Her role includes overall responsibility for the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox). She will be part of the company's management team and will take up her position on February 20, 2023. Pia Baumann, who is an MD specialized in oncology and earned her Ph.D. at Karolinska

Nomination Committee RugVista Group AB (publ) appointed

The Nomination Committee of RugVista Group AB (publ) (“RugVista”) has been formed in accordance with the company’s “Instruction for the Nomination Committee” as adopted by the Annual General Meeting. The Nomination Committee appointed for RugVista’s 2023 Annual General Meeting has the following composition: · Gunnar Mattsson (representative of madHat AB, and chairperson of the Nomination Committee) · Klara Hanzon (representative of TIN Ny Teknik) · Erik Lindgren (chairperson of RugVista’s Board of Directors) Shareholders who wish to submit proposals to the Nomination Committee

BioStock: Pricing in focus for Respiratorius ahead of partnering discussions

Oncology company Respiratorius are now working on marketing VAL001 with the aim of securing a partnership. A new formulation and the possibility of differentiation from already available products is considered the single most important component to ensure attractive pricing for an upcoming market launch. In this article, BioStock looks at the company’s own pricing analysis and the market potential that it believes the project possesses.Read the full article at biostock.se: https://www.biostock.se/en/2022/11/pricing-in-focus-for-respiratorius-ahead-of-partnering-discussions/ This is a

Nordhealth AS - Invitation to Q3 2022 presentation

Nordhealth will report and present its Q3 2022 results on Friday the 25th of November 2022.The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 25th of November at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/82134750106 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q3 will be available on 25 November 2022 at 07:30 am CET on www.newsweb.no and on Nordhealth's IR website https://nordhealth.com/investor/news-and-

Idogen’s scientific adviser Jan Holgersson strengthens the company’s Board of Directors

Idogen AB (publ) announced today that Jan Holgersson, who has served for several years as scientific adviser to the company, has agreed to strengthen the company’s Board of Directors in the role as co-opted Board member.   Jan Holgersson is a professor of Transplant Immunology at Gothenburg University, the Medical Director of the Tissue Typing and Stem Cell Laboratories at Sahlgrenska University Hospital in Gothenburg, where he was also formerly the Head of Clinical Immunology and Transfusion Medicine. His research focuses on understanding the immunological mechanisms that underlie

Nordic Nanovector comment on Proposed Merger with APIM Therapeutics

Oslo, Norway, 21 November 2022 Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") desires to share more information with the Company’s shareholders about the proposed merger between the Company and APIM Therapeutics (“APIM”). The Company has scheduled a webcast, including a question and answers session, on Thursday, November 24 at 4.30 CET. Practical details regarding the webcast will be issued in a separate notice. Any questions may be submitted to ir@nordicnanovector.com. The Board of Nordic Nanovector and its advisors reiterates its belief that the merger

Genetic Analysis AS announces the outcome of the warrant exercise

Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS's ("GA" or the "Company") warrants of series TO 1, issued in connection with the Company's IPO of units in September/October 2021, ended. No warrants of series TO 1 have been exercised. The reason for this is deemed to be that the subscription price for the exercise of warrants of series TO 1 has exceeded the current share price during the entire exercise period.During the period November 2 until November 16, 2022, holders of warrants of series TO 1 were, for each warrant, entitled to

Kindred challenges the coercive fine in Norway

Kindred Group, via its wholly owned Maltese subsidiary Trannel International Ltd, has been informed that the Norwegian Gaming Authority has decided to reinstate the coercive fine against Trannel International despite the changes Kindred Group has undertaken. Kindred Group disagrees with the legal basis for the non-enforceable fine and will continue to challenge this in the courts.Kindred Group plc (Kindred) has during the past month, via its wholly owned Maltese subsidiary Trannel International Ltd (Trannel), performed several changes in its offering to ensure compliance with the

Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference

Stockholm, November 21, 2022 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 confirmatory Clarity AD clinical trial for lecanemab[1] (development code: BAN2401), at the 15[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in San Francisco, CA and virtually from November 29 to December 2. The data will be presented by Eisai and distinguished faculty members in a scientific session on the first day of the meeting (November 29 at 4:50 p.m. PT). Additionally, BioArctic will present a poster

Africa Oil announces results of share buyback program

November 21, 2022 (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased to announce that the Company repurchased a total of 1,667,480 Africa Oil common shares during the period of November 14, 2022 to November 18, 2022 under the previously announced share buyback program. View PDF version  The launch of Africa Oil’s normal course issuer bid (share buyback) program, announced by the Company on September 22, 2022, is being implemented in accordance with the Market Abuse Regulation (EU)

First Camp considers issuance of sustainability linked bonds and announces conditional tender offer and notice of early redemption for the outstanding 2019/2023 bonds

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) (THE "SECURITIES ACT") OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR,

Research: urban residents want to invest in the development of public transport, cycling and walking

YIT Corporation Press release 21 November 2022 at 9:00 a.m.According to a barometer commissioned by YIT, when asked about the three main modes of transport that urban residents would like to see investment in, the most important in cities are public transport (50% of respondents), cycling (47%) and walking (45%).  The importance of good public transport connections and cycle paths has continued to increase in the appreciation of one’s own residential area from 47% in 2021 to 58% in 2022. Their importance is highlighted in Helsinki, Tampere, Turku, Oulu and Jyväskylä.  Residents want

Mycronic receives order for an SLX mask writer

Mycronic AB (publ) has received an order for an SLX mask writer from a new customer in Asia. The order value is in the range of USD 4-6 million. Delivery of the system is planned for the fourth quarter of 2023.The SLX laser mask writer meets rising demand for photomasks for the semiconductor industry and a future need for replacement and modernization. Photomasks manufactured by laser mask writers are of high importance and account for 70-75 percent of all photomasks produced for semiconductor manufacturing. SLX is a modern and energy efficient mask writer based on the same technology as

Veidekke: Mandatory notification of trade - Shares purchased by Key employees in 2022

A total of 600 participants in the Company's share programme for key employees have on November 18[th] 2022 subscribed for 747 111 shares. The purchase price is equal to the volume-weighted average share price on the Oslo Stock Exchange in the subscription period, with a deduction for a discount. Discount for Swedish employees is 25 % which gives a purchase price of 67.64 NOK per share. For the Norwegian and the Danish employee`s the discount is 20%, which gives a purchase price of 72.14 NOK per share. The shares are subject to a three-year lock-in period. A total of 535

Veidekke: Exercise of employee share options in Veidekke ASA

A total of 44 participants in the Company's share option programme have on November 18[th] 2022 exercised a total of 21 425 options at a strike price of NOK 50.80.A total of 36 participants in the Company's share option programme have on November 18[th] 2022 exercised a total of 18 055 options at a strike price of NOK 55.11.Following the exercise, the employees will purchase 39 480 shares. These shares will be transferred in December. From the total above, 250 options have been exercised by primary insiders. The following primary insider has been exercised options: Anne

Peab rebuilds Högland Hospital in Eksjö

Peab has been commissioned to rebuild sections of Högland Hospital in Eksjö. The customer is regional properties, Region Jönköping County and the contract is worth SEK 300 million.Peab is commencing the work on part B of the Högland Hospital which entails renovation of the centrally located buildings 06 and 25, which include the ER. Renovation to meet the demands on a modern healthcare environment will be done in several stages. The goal is a hospital that will function well for a long time to come with flexible and generally designed rooms along with technical systems that enable easy

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseNovember 21, 2022, at 9.00 am EETRepurchase of Outokumpu’s own shares On November 18, 2022, Outokumpu has completed repurchases its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |65,879 |4.6867

GREENFOOD’S INTERIM REPORT THIRD QUARTER 2022

The third quarter of the year was characterised by a robust performance despite upstream cost inflation and more price-sensitive consumers.INTERIM OVERVIEW 1 JULY – 30 SEPTEMBER · Net sales for the period totalled SEK 1,302.2 million (1,100.1) an increase of 18.4%, whereof about 8% related to inflation driven cost increases. · Adjusted EBITDA improved significantly with SEK 14.2 million to SEK 88.5 million (74.3) compared with the third quarter 2021. · Operating profit/loss amounted to SEK 22.0 million compared with 2021 (-16,3) an improvement of SEK 38,3 million. The difference

Skanska improves facility in Houston, Texas, USA, for USD 58M, about SEK 580M

Skanska and its joint venture partner, Indi Construction Partners LLC, signed a contract for design-build services to a facility in Houston, Texas, USA. The contract is worth in total USD 64M, about SEK 640M. Skanska’s portion is worth USD 58M, about SEK 580M, which will be included in the US order bookings for the fourth quarter of 2022.Supplemental tenant improvements will be made to a 130,000 square meter facility resulting in a new receiving center. The project scope includes pick module and pallet rack installation, MEP systems, and office build-out. Construction is slated to begin

Noreco: Specification of Timeline and Settlement Mechanics relating to the Proposed Amendments to the NOR13 Subordinated Convertible Bond Terms

Oslo, 21 November 2022: Reference is made to the stock exchange notices published on 8 November 2022 where Norwegian Energy Company ASA ("Noreco" or the "Company") announced summons for a written resolution (the “Summons”) with proposed amendments to the Company's outstanding USD 165,229,319 2019/2027 convertible bond loan with ISIN NO0010851520 issued by Noreco and listed on Oslo Børs (“NOR13”), and that the written resolution in respect of the NOR13 amendments had been resolved and approved by the Company's bondholders. The amendments to the NOR13 bond terms (“Bond Terms”) pursuant to the

Profit warning: Pihlajalinna revises guidance for 2022

Pihlajalinna Plc           Insider Information           21 November 2022 at 8:00 a.m.Profit warning: Pihlajalinna revises guidance for 2022Pihlajalinna’s revenue has increased as expected following the planned supply growth. However, the expansion of the service network and the supply growth as well as the lower demand of the Covid-19 services compared to previous year and high employee expenses including sick leaves due to the Covid-19 pandemic has burdened the profitability. In addition, the business arrangements synergies have been delayed. Pihlajalinna revises guidance for the full

There are no items matching the current filter
There are no more items matching the current filter
Back to top